Literature DB >> 7492119

Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.

P L Boyer1, S H Hughes.   

Abstract

We have analyzed recombinant human immunodeficiency virus type 1 reverse transcriptases that contain mutations at position 184. These variants retain high levels of RNA-dependent DNA polymerase activity and show resistance to ddITP. However, the mutants varied in their ability to polymerize processively. The variants Met184Ile and Met184Val showed slight reductions in processivity relative to that of the wild-type enzyme; the variants Met184Ala and Met184Leu showed considerable reductions in their processivity.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7492119      PMCID： PMC162796          DOI： 10.1128/AAC.39.7.1624

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Cassette mutagenesis of the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  P L Boyer; A L Ferris; S H Hughes
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

2.  Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV.

Authors:  F di Marzo Veronese; T D Copeland; A L DeVico; R Rahman; S Oroszlan; R C Gallo; M G Sarngadharan
Journal:  Science       Date:  1986-03-14       Impact factor: 47.728

3.  Reconstitution and properties of homologous and chimeric HIV-1.HIV-2 p66.p51 reverse transcriptase.

Authors:  K J Howard; K B Frank; I S Sim; S F Le Grice
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

4.  Expression of soluble, enzymatically active, human immunodeficiency virus reverse transcriptase in Escherichia coli and analysis of mutants.

Authors:  A Hizi; C McGill; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

5.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

6.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor.

Authors:  L A Kohlstaedt; J Wang; J M Friedman; P A Rice; T A Steitz
Journal:  Science       Date:  1992-06-26       Impact factor: 47.728

7.  Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations.

Authors:  E Arnold; A Jacobo-Molina; R G Nanni; R L Williams; X Lu; J Ding; A D Clark; A Zhang; A L Ferris; P Clark
Journal:  Nature       Date:  1992-05-07       Impact factor: 49.962

Review 8.  Retroviruses.

Authors:  H Varmus
Journal:  Science       Date:  1988-06-10       Impact factor: 47.728

9.  Subunit-selective mutagenesis indicates minimal polymerase activity in heterodimer-associated p51 HIV-1 reverse transcriptase.

Authors:  S F Le Grice; T Naas; B Wohlgensinger; O Schatz
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

10.  Identification and characterization of HIV-specific RNase H by monoclonal antibody.

Authors:  J Hansen; T Schulze; W Mellert; K Moelling
Journal:  EMBO J       Date:  1988-01       Impact factor: 11.598
View more
  43 in total

1.  Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

Authors:  P L Sharma; C S Crumpacker
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Analysis of mutations at positions 115 and 116 in the dNTP binding site of HIV-1 reverse transcriptase.

Authors:  P L Boyer; S G Sarafianos; E Arnold; S H Hughes
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

3.  Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching.

Authors:  E S Svarovskaia; K A Delviks; C K Hwang; V K Pathak
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 4.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity.

Authors:  E K Halvas; E S Svarovskaia; V K Pathak
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

8.  Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.

Authors:  Lu Gao; Mark Nils Hanson; Mini Balakrishnan; Paul L Boyer; Bernard P Roques; Stephen H Hughes; Baek Kim; Robert A Bambara
Journal:  J Biol Chem       Date:  2008-01-24       Impact factor: 5.157

9.  The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.

Authors:  Robert W Shafer; Rami Kantor; Matthew J Gonzales
Journal:  AIDS Rev       Date:  2000       Impact factor: 2.500

Review 10.  Clinical pharmacokinetics of lamivudine.

Authors:  M A Johnson; K H Moore; G J Yuen; A Bye; G E Pakes
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.